Fourth Quarter 2025 Financial Results Summary:
- Net product revenue of
$225.1 million for the fourth quarter of 2025, an increase of$98.4 million compared to net product revenue of$126.7 million for the fourth quarter of 2024. Net product revenue for the fourth quarter of 2025 consists of:- Net product revenue from Advanced Wound Care products of
$217.2 million , an increase of 83% from the fourth quarter of 2024. - Net product revenue from Surgical & Sports Medicine products of
$7.9 million , a decrease of 2% from the fourth quarter of 2024.
- Net product revenue from Advanced Wound Care products of
- Net income of
$43.7 million for the fourth quarter of 2025, compared to net income of$7.7 million for the fourth quarter of 2024, an increase in net income of$36.0 million . - Adjusted EBITDA of
$84.2 million for the fourth quarter of 2025, compared to Adjusted EBITDA of$18.2 million for the fourth quarter of 2024, an increase of$66.0 million . - Adjusted net income of
$52.9 million for the fourth quarter of 2025, compared to adjusted net income of$8.8 million for the fourth quarter of 2024, an increase of$44.1 million .
Fiscal Year 2025 Financial Results Summary:
- Net product revenue of
$563.0 million for the year endedDecember 31, 2025 , an increase of$81.0 million compared to net product revenue of$482.0 million for the year endedDecember 31, 2024 . Net product revenue for the year endedDecember 31, 2025 consists of:- Net product revenue from Advanced Wound Care products of
$531.2 million , an increase of 17% year over year. - Net product revenue from Surgical & Sports Medicine products of
$31.8 million , an increase of 12% year over year.
- Net product revenue from Advanced Wound Care products of
- Net income of
$37.0 million for the year endedDecember 31, 2025 , compared to net income of$0.9 million for the year endedDecember 31, 2024 , an increase of$36.2 million . - Adjusted EBITDA of
$98.1 million for the year endedDecember 31, 2025 , compared to Adjusted EBITDA of$49.8 million for the year endedDecember 31, 2024 , an increase of$48.4 million . - Adjusted net income of
$55.2 million for the year endedDecember 31, 2025 , compared to adjusted net income of$20.5 million for the year endedDecember 31, 2024 , an increase of$34.7 million .
“We delivered record performance in 2025 by demonstrating a sustained ability to execute on our strategy in a complex and challenging market,” said
Fourth Quarter 2025 Financial Results:
| Three Months Ended | Change | |||||||||||||||
| 2025 | 2024 | $ | % | |||||||||||||
| (in thousands, except for percentages) | ||||||||||||||||
| Advanced | $ | 217,168 | $ | 118,585 | $ | 98,583 | 83 | % | ||||||||
| Surgical & Sports Medicine | 7,903 | 8,071 | (168 | ) | (2 | %) | ||||||||||
| Net product revenue | $ | 225,071 | $ | 126,656 | $ | 98,415 | 78 | % | ||||||||
Net product revenue for the fourth quarter of 2025 was
Gross profit for the fourth quarter of 2025 was
Operating expenses for the fourth quarter of 2025 were
Operating income for the fourth quarter of 2025 was
Total other income (expense), net, for the fourth quarter of 2025 was
Net income for the fourth quarter of 2025 was
Adjusted EBITDA was
Adjusted net income was
Non-GAAP operating income was
Fiscal Year 2025 Financial Results:
| Year Ended | Change | |||||||||||||||
| 2025 | 2024 | $ | % | |||||||||||||
| (in thousands, except for percentages) | ||||||||||||||||
| Advanced | $ | 531,242 | $ | 453,639 | $ | 77,603 | 17 | % | ||||||||
| Surgical & Sports Medicine | 31,788 | 28,404 | 3,384 | 12 | % | |||||||||||
| Net product revenue | $ | 563,030 | $ | 482,043 | $ | 80,987 | 17 | % | ||||||||
Net product revenue for the year ended
Gross profit for the year ended
Operating expenses for the year ended
Operating income for the year ended
Total other income (expense), net, for the year ended
Net income for the year ended
Adjusted EBITDA was
Adjusted net income was
Non-GAAP operating income was
As of
Fiscal Year 2026 Outlook:
For the year ending
- Total net revenue between
$350.0 million and$420.0 million , representing a decline in the range of 25% to 38%, as compared to total net revenue of$564.2 million for the year endedDecember 31, 2025 .- The 2026 total net revenue guidance range assumes a significant year-over-year decline in revenue for the three months ending
March 31, 2026 , and strong quarter-over-quarter growth in the second, third and fourth quarters of fiscal year 2026.
- The 2026 total net revenue guidance range assumes a significant year-over-year decline in revenue for the three months ending
Fourth Quarter Earnings Conference Call:
Management will host a conference call at
UNAUDITED CONSOLIDATED BALANCE SHEETS (amounts in thousands, except share and per share data) | ||||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 93,679 | $ | 135,571 | ||||
| Restricted cash | 652 | 580 | ||||||
| Accounts receivable, net of allowance for credit losses of | 217,451 | 109,861 | ||||||
| Inventories, net | 29,627 | 26,219 | ||||||
| Asset held for sale (Note 8) | 2,425 | — | ||||||
| Prepaid expenses and other current assets | 18,354 | 13,710 | ||||||
| Total current assets | 362,188 | 285,941 | ||||||
| Property and equipment, net | 103,711 | 89,128 | ||||||
| Intangible assets, net | 9,145 | 12,468 | ||||||
| 28,772 | 28,772 | |||||||
| Operating lease right-of-use assets, net | 55,749 | 37,110 | ||||||
| Deferred tax asset, net | 29,962 | 39,462 | ||||||
| Other assets | 9,203 | 5,005 | ||||||
| Total assets | $ | 598,730 | $ | 497,886 | ||||
| Liabilities, Redeemable Convertible Preferred Stock, and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Current portion of finance lease obligations | $ | 9,435 | $ | 1,170 | ||||
| Current portion of operating lease obligations - related party | 4,258 | 3,671 | ||||||
| Current portion of operating lease obligations | 4,949 | 4,272 | ||||||
| Accounts payable | 31,949 | 28,911 | ||||||
| Accrued expenses and other current liabilities | 49,533 | 39,453 | ||||||
| Total current liabilities | 100,124 | 77,477 | ||||||
| Finance lease obligations, net of current portion | 12,788 | 718 | ||||||
| Operating lease obligations, net of current portion - related party | 28,237 | 8,283 | ||||||
| Operating lease obligations, net of current portion | 22,470 | 25,198 | ||||||
| Other liabilities | 1,193 | 894 | ||||||
| Total liabilities | 164,812 | 112,570 | ||||||
| Commitments and contingencies (Note 20) | ||||||||
| Series A redeemable convertible preferred stock, | 133,789 | 122,419 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, | — | — | ||||||
| Common stock, | 13 | 13 | ||||||
| Additional paid-in capital | 303,194 | 302,994 | ||||||
| Accumulated deficit | (3,078 | ) | (40,110 | ) | ||||
| Total stockholders' equity | 300,129 | 262,897 | ||||||
| Total liabilities, redeemable convertible preferred stock, and stockholders' equity | $ | 598,730 | $ | 497,886 | ||||
(amounts in thousands, except share and per share data) | ||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue: | ||||||||||||||||
| Net product revenue | $ | 225,071 | $ | 126,656 | $ | 563,030 | $ | 482,043 | ||||||||
| Grant income | 536 | — | 1,139 | — | ||||||||||||
| Total revenue | 225,607 | 126,656 | 564,169 | 482,043 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of goods sold | 49,918 | 31,051 | 137,522 | 115,741 | ||||||||||||
| Selling, general and administrative | 100,174 | 73,856 | 326,236 | 294,513 | ||||||||||||
| Research and development | 10,286 | 11,530 | 44,542 | 50,271 | ||||||||||||
| Write-down to fair value for asset held for sale | 1,940 | — | 11,175 | — | ||||||||||||
| Impairment of property and construction | — | — | — | 18,842 | ||||||||||||
| Write-down of capitalized internal-use software costs | — | — | — | 3,959 | ||||||||||||
| Total operating expenses | 162,318 | 116,437 | 519,475 | 483,326 | ||||||||||||
| Income (loss) from operations | 63,289 | 10,219 | 44,694 | (1,283 | ) | |||||||||||
| Other income (expense), net: | ||||||||||||||||
| Interest income (expense), net | 236 | 61 | 2,281 | (1,544 | ) | |||||||||||
| Other income (expense), net | (98 | ) | (27 | ) | (5 | ) | 20 | |||||||||
| Total other income (expense), net | 138 | 34 | 2,276 | (1,524 | ) | |||||||||||
| Net income (loss) before income taxes | 63,427 | 10,253 | 46,970 | (2,807 | ) | |||||||||||
| Income tax benefit (expense) | (19,727 | ) | (2,580 | ) | (9,938 | ) | 3,668 | |||||||||
| Net income and comprehensive income | 43,700 | 7,673 | 37,032 | 861 | ||||||||||||
| Accretion of redeemable convertible preferred stock to redemption value | (150 | ) | (412 | ) | (540 | ) | (412 | ) | ||||||||
| Cumulative dividend on redeemable convertible preferred stock | (2,788 | ) | (1,386 | ) | (10,830 | ) | (1,386 | ) | ||||||||
| Undistributed earnings allocated to participating redeemable convertible preferred stock | (9,228 | ) | (738 | ) | (5,640 | ) | — | |||||||||
| Net income (loss) attributable to common stockholders | $ | 31,534 | $ | 5,137 | $ | 20,022 | $ | (937 | ) | |||||||
| Net income (loss) per share: | ||||||||||||||||
| Basic | $ | 0.25 | $ | 0.04 | $ | 0.16 | $ | (0.01 | ) | |||||||
| Diluted | $ | 0.24 | $ | 0.04 | $ | 0.15 | $ | (0.01 | ) | |||||||
| Weighted-average common shares outstanding | ||||||||||||||||
| Basic | 126,913,293 | 129,679,843 | 126,738,136 | 131,673,278 | ||||||||||||
| Diluted | 132,206,983 | 132,162,370 | 130,248,412 | 131,673,278 | ||||||||||||
(amounts in thousands, except share and per share data) | ||||||||||||
| Year Ended | ||||||||||||
| 2025 | 2024 | 2023 | ||||||||||
| Cash flows from operating activities: | ||||||||||||
| Net income | $ | 37,032 | $ | 861 | $ | 4,945 | ||||||
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ||||||||||||
| Depreciation and amortization | 15,273 | 13,623 | 10,448 | |||||||||
| Amortization of intangible assets | 3,323 | 3,403 | 4,918 | |||||||||
| Reduction in the carrying value of right-of-use assets | 8,342 | 8,348 | 8,083 | |||||||||
| Non-cash interest expense | 375 | 394 | 427 | |||||||||
| Deferred interest expense | — | 305 | 490 | |||||||||
| Deferred tax expense (benefit) | 9,500 | (10,719 | ) | 2,012 | ||||||||
| Loss on disposal of property and equipment | 188 | 1,140 | 235 | |||||||||
| Loss on lease termination | — | — | 559 | |||||||||
| Loss on extinguishment of term loan | — | 215 | — | |||||||||
| Provision recorded for credit losses | 8,213 | 3,938 | 1,297 | |||||||||
| Adjustment for excess and obsolete inventories | 15,353 | 8,210 | 6,580 | |||||||||
| Stock-based compensation | 13,298 | 10,578 | 8,996 | |||||||||
| Write-down to fair value for asset held for sale (Note 8) | 11,175 | — | — | |||||||||
| Impairment of property and construction (Note 8) | — | 18,842 | — | |||||||||
| Write-down of capitalized internal-use software costs (Note 8) | — | 3,959 | — | |||||||||
| Changes in operating assets and liabilities: | ||||||||||||
| Accounts receivable | (115,803 | ) | (31,800 | ) | 5,539 | |||||||
| Inventories | (17,915 | ) | (6,204 | ) | (8,179 | ) | ||||||
| Prepaid expenses and other current and other assets | (183 | ) | (2,549 | ) | (10,115 | ) | ||||||
| Operating leases | (8,491 | ) | (14,066 | ) | (8,439 | ) | ||||||
| Accounts payable | (528 | ) | (2,372 | ) | (108 | ) | ||||||
| Accrued expenses and other current liabilities | 10,381 | 9,164 | 3,138 | |||||||||
| Other liabilities | 158 | (1,062 | ) | 91 | ||||||||
| Net cash provided by (used in) operating activities | (10,309 | ) | 14,208 | 30,917 | ||||||||
| Cash flows from investing activities: | ||||||||||||
| Purchases of property and equipment | (14,151 | ) | (10,032 | ) | (24,364 | ) | ||||||
| Net cash used in investing activities | (14,151 | ) | (10,032 | ) | (24,364 | ) | ||||||
| Cash flows from financing activities: | ||||||||||||
| Construction of landlord assets, net of tenant allowance | (14,461 | ) | — | — | ||||||||
| Term loan repayments under the 2021 Credit Agreement | — | (66,563 | ) | (4,688 | ) | |||||||
| Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs | — | 120,688 | — | |||||||||
| Payments for the repurchase of common stock | — | (25,479 | ) | — | ||||||||
| Principal repayments of finance lease obligations | (1,171 | ) | (1,081 | ) | (485 | ) | ||||||
| Proceeds from the exercise of stock options | 157 | 1,247 | — | |||||||||
| Payments of withholding taxes in connection with RSUs vesting | (1,885 | ) | (1,175 | ) | (332 | ) | ||||||
| Net cash provided by (used in) financing activities | (17,360 | ) | 27,637 | (5,505 | ) | |||||||
| Change in cash, cash equivalents and restricted cash | (41,820 | ) | 31,813 | 1,048 | ||||||||
| Cash, cash equivalents, and restricted cash, beginning of year | 136,151 | 104,338 | 103,290 | |||||||||
| Cash, cash equivalents, and restricted cash, end of year | $ | 94,331 | $ | 136,151 | $ | 104,338 | ||||||
| Supplemental disclosure of cash flow information: | ||||||||||||
| Cash paid for interest | $ | — | $ | 4,970 | $ | 5,436 | ||||||
| Cash paid for income taxes | $ | 5,346 | $ | 6,965 | $ | 3,052 | ||||||
| Supplemental disclosure of non-cash investing and financing activities: | ||||||||||||
| Cumulative effect adjustment for adoption of ASU No. 2016-13 | $ | — | $ | — | $ | 615 | ||||||
| Change in purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities | $ | 715 | $ | (432 | ) | $ | 841 | |||||
| Right-of-use assets obtained through operating lease obligations | $ | 26,981 | $ | 5,109 | $ | 5,869 | ||||||
| Right-of-use assets obtained through finance lease obligations | $ | 21,506 | $ | — | $ | 3,454 | ||||||
| Redeemable convertible preferred stock issuance costs included in accrued expenses | $ | — | $ | 67 | $ | — | ||||||
| Prepaid rent reclassified to right-of-use assets | $ | — | $ | 230 | $ | — | ||||||
| Landlord asset additions included in accounts payable and other liabilities, net of tenant allowances | $ | 2,691 | $ | — | $ | — | ||||||
| Accretion to redemption value and cumulative dividends on redeemable convertible preferred stock | $ | 11,370 | $ | 1,798 | $ | — | ||||||
Non-GAAP Financial Measures
Our management uses financial measures that are not in accordance with generally accepted accounting principles in
Adjusted EBITDA
Adjusted EBITDA consists of GAAP net income excluding: (i) interest expense (income), net, (ii) income tax expense (benefit), (iii) depreciation and amortization, (iv) amortization of intangible assets, (v) stock-based compensation expense, and (vi) additional infrequently occurring adjustments described in more detail below.
The following table presents a reconciliation of GAAP net income to non-GAAP EBITDA and non-GAAP Adjusted EBITDA, for the periods presented:
| Three Months Ended | Year Ended | |||||||||||||||
| ($, in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Net income | $ | 43,700 | $ | 7,673 | $ | 37,032 | $ | 861 | ||||||||
| Interest expense (income), net | (236 | ) | (61 | ) | (2,281 | ) | 1,544 | |||||||||
| Income tax expense (benefit) | 19,727 | 2,580 | 9,938 | (3,668 | ) | |||||||||||
| Depreciation and amortization | 4,066 | 3,615 | 15,273 | 13,623 | ||||||||||||
| Amortization of intangible assets | 798 | 834 | 3,323 | 3,403 | ||||||||||||
| EBITDA | 68,055 | 14,641 | 63,285 | 15,763 | ||||||||||||
| Stock-based compensation expense | 4,324 | 2,891 | 13,298 | 10,578 | ||||||||||||
| Write-down to fair value for asset held for sale (1) | 1,940 | — | 11,175 | — | ||||||||||||
| Restructuring charge (2) | — | — | 516 | — | ||||||||||||
| Impairment of property and construction (3) | — | — | — | 18,842 | ||||||||||||
| Write-down of capitalized software costs (4) | — | — | — | 3,959 | ||||||||||||
| Disposal of construction in progress (5) | — | 645 | — | 645 | ||||||||||||
| FDA BLA fees for ReNu (6) | 4,682 | — | 4,682 | — | ||||||||||||
| PFS regulation related charges (7) | 3,723 | — | 3,723 | — | ||||||||||||
| Inventory write-downs (8) | 1,458 | — | 1,458 | — | ||||||||||||
| Adjusted EBITDA | $ | 84,182 | $ | 18,177 | $ | 98,137 | $ | 49,787 | ||||||||
(1) Amount reflects the fair value adjustment of a purchased building classified as held for sale.
(2) Amounts reflect employee retention and benefits as well as other exit costs associated with our restructuring activities.
(3) Amount reflects the impairment of a purchased building and associated unfinished construction work.
(4) Amount reflects the write-down of costs previously capitalized as construction in progress in the development of internal-use software, that the Company determined have no future value.
(5) Amount reflects construction in progress terminated and disposed of at one of our
(6) Amount reflects fees paid to the FDA in connection with the ReNu BLA filing.
(7) Amount reflects non-recurring inventory write-down adjustments for excess and obsolete inventory resulting from a shift in product lines due to the Physician Fee Schedule (“PFS”) regulatory changes of
(8) Amount reflects non-recurring inventory write-down adjustments for excess and obsolete inventory resulting from a one-time loss of key distributor in a certain international location.
Adjusted net income
Adjusted net income is defined as GAAP net income plus (i) amortization of intangible assets and (ii) additional infrequently occurring adjustments described in more detail below, less the estimated tax on these adjustments.
The following table presents a reconciliation of GAAP net income to non-GAAP Adjusted net income, for the periods presented:
| Three Months Ended | Year Ended | |||||||||||||||
| ($, in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Net income | $ | 43,700 | $ | 7,673 | $ | 37,032 | $ | 861 | ||||||||
| Amortization of intangible assets | 798 | 834 | 3,323 | 3,403 | ||||||||||||
| Write-down to fair value for asset held for sale (1) | 1,940 | — | 11,175 | — | ||||||||||||
| Restructuring charge (2) | — | — | 516 | — | ||||||||||||
| Impairment of property and construction (3) | — | — | — | 18,842 | ||||||||||||
| Write-down of capitalized software costs (4) | — | — | — | 3,959 | ||||||||||||
| Disposal of construction in progress (5) | — | 645 | — | 645 | ||||||||||||
| FDA BLA fees for ReNu (6) | 4,682 | — | 4,682 | — | ||||||||||||
| PFS regulation related charges (7) | 3,723 | — | 3,723 | — | ||||||||||||
| Inventory write-downs (8) | 1,458 | — | 1,458 | — | ||||||||||||
| Tax on above | (3,402 | ) | (399 | ) | (6,717 | ) | (7,249 | ) | ||||||||
| Adjusted net income | $ | 52,899 | $ | 8,753 | $ | 55,192 | $ | 20,461 | ||||||||
(1) Amount reflects the fair value adjustment of a purchased building classified as held for sale.
(2) Amounts reflect employee retention and benefits as well as other exit costs associated with our restructuring activities.
(3) Amount reflects the impairment of a purchased building and associated unfinished construction work.
(4) Amount reflects the write-down of costs previously capitalized as construction in progress in the development of internal-use software, that the Company determined have no future value.
(5) Amount reflects construction in progress terminated and disposed of at one of our
(6) Amount reflects fees paid to the FDA in connection with the ReNu BLA filing.
(7) Amount reflects non-recurring inventory write-down adjustments for excess and obsolete inventory resulting from a shift in product lines due to PFS regulatory changes of
(8) Amount reflects non-recurring inventory write-down adjustments for excess and obsolete inventory resulting from a one-time loss of key distributor in a certain international location.
Non-GAAP Operating Income
Non-GAAP operating income is defined as GAAP income (loss) from operations plus (i) amortization of intangible assets and (ii) additional infrequently occurring adjustments described in more detail below.
The following table presents a reconciliation of GAAP income (loss) from operations to non-GAAP operating income, for the periods presented:
| Three Months Ended | Year Ended | |||||||||||||||
| ($, in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Income (loss) from operations | $ | 63,289 | $ | 10,219 | $ | 44,694 | $ | (1,283 | ) | |||||||
| Amortization of intangible assets | 798 | 834 | 3,323 | 3,403 | ||||||||||||
| Write-down to fair value for asset held for sale (1) | 1,940 | — | 11,175 | — | ||||||||||||
| Restructuring charge (2) | — | — | 516 | — | ||||||||||||
| Impairment of property and construction (3) | — | — | — | 18,842 | ||||||||||||
| Write-down of capitalized software costs (4) | — | — | — | 3,959 | ||||||||||||
| Disposal of construction in progress (5) | — | 645 | — | 645 | ||||||||||||
| FDA BLA fees for ReNu (6) | 4,682 | — | 4,682 | — | ||||||||||||
| PFS regulation related charges (7) | 3,723 | — | 3,723 | — | ||||||||||||
| Inventory write-downs (8) | 1,458 | — | 1,458 | — | ||||||||||||
| Non-GAAP operating income | $ | 75,890 | $ | 11,698 | $ | 69,571 | $ | 25,566 | ||||||||
(1) Amount reflects the fair value adjustment of a purchased building classified as held for sale.
(2) Amounts reflect employee retention and benefits as well as other exit costs associated with our restructuring activities.
(3) Amount reflects the impairment of a purchased building and associated unfinished construction work.
(4) Amount reflects the write-down of costs previously capitalized as construction in progress in the development of internal-use software, that the Company determined have no future value.
(5) Amount reflects construction in progress terminated and disposed of at one of our
(6) Amount reflects fees paid to the FDA in connection with the ReNu BLA filing.
(7) Amount reflects non-recurring inventory write-down adjustments for excess and obsolete inventory resulting from a shift in product lines due to PFS regulatory changes of
(8) Amount reflects non-recurring inventory write-down adjustments for excess and obsolete inventory resulting from a one-time loss of key distributor in a certain international location.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “assume,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements relating to the Company’s expected quarterly and annual revenue for fiscal 2026, the Company’s expectations regarding the impact of CMS’ updated 2026 Medicare reimbursement and coverage changes, and the Company’s longer-term expectations regarding market share gains, opportunities and growth. Forward-looking statements with respect to the operations of the Company, strategies, prospects, and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the coverage and reimbursement levels for the Company’s products, particularly in light of CMS’ updated 2026 Medicare reimbursement and coverage changes; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company’s ability to raise funds to expand its business; (6) the Company has incurred losses in the prior periods and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company’s ability to maintain production or obtain supply of its products in sufficient quantities to meet demand; (10) the Company’s ability to build out its
About
Investor Inquiries:ICR Healthcare Mike Piccinino , CFAOrganoIR@icrinc.comPress and Media Inquiries:Organogenesiscommunications@organo.com
